Bowel Preparation May Lead to a Higher Feasibility of Intestinal Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-15

Study Completion Date

2022-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An adequate bowel preparation is essential for a high quality of colonscopy. Nowdays, polyethyleneglyco is considered the most safe drug for bowel preparation, and is widely used around the world. However, previous study illustrated that bowel preparation by polyethyleneglyco could lead to qualitative changes in the intestinal microbiota both in mice and human. This study is aimed to investigate wether the changes in the intestinal microbiota could lead to a higher rate of intestinal infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy

NCT03352700

Bowel Preparation Scale the Amount of Air Bubble Adenoma Detection Rate

UNKNOWN PHASE4

A Prospective Study of the Effect of Modified Colonoscopy Bowel Preparation Program on Intestinal Cleaning, Examination and Disease in Patients With Inflammatory Bowel Disease

NCT05485103

Inflammatory Bowel Diseases

UNKNOWN NA

Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy

NCT02507037

Bowel Preparation Scale Adenoma Detection Rate

COMPLETED PHASE4

The Comparative Study Between Bowel Preparation Method

NCT01964417

Colonoscopy

COMPLETED PHASE3

Bowel Preparation for Colonoscopy in the Elderly

NCT02290093

Bowel Preparation Colonoscopy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

polyethyleneglycol only

participants take 2L of polyethyleneglycol only

Group Type EXPERIMENTAL

2L of polyethyleneglycol

Intervention Type DRUG

2L of polyethyleneglycol

polyethyleneglycol puls Inulin

participants take 2L of polyethyleneglycol, subsequently take 15g inulin per day.

Group Type EXPERIMENTAL

2L of polyethyleneglycol

Intervention Type DRUG

2L of polyethyleneglycol

inulin

Intervention Type DIETARY_SUPPLEMENT

15g inulin per day

polyethyleneglycol puls probiotic combination product

Participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named "Mei Ri Yi Jun" was produced by Wedge Pharmaceuticals.

Group Type EXPERIMENTAL

2L of polyethyleneglycol

Intervention Type DRUG

2L of polyethyleneglycol

probiotic combination product

Intervention Type COMBINATION_PRODUCT

participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named "Mei Ri Yi Jun" was produced by Wedge Pharmaceuticals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2L of polyethyleneglycol

Intervention Type DRUG

inulin

15g inulin per day

Intervention Type DIETARY_SUPPLEMENT

probiotic combination product

participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named "Mei Ri Yi Jun" was produced by Wedge Pharmaceuticals.

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who agree to participant in the study

Exclusion Criteria

* patients who couldn't stand polyethyleneglycol or inulin patients couldn't provide Informed consent patients who are suffering from sever heart disease, pulmonary disease or renal dysfunction.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes